STAA · XBRL financial data

STAAR Surgical financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (STAA's year ends in early January)

In thousands of dollars	FY 2020Jan 1, 2021	FY 2021Dec 31, 2021	FY 2022Dec 30, 2022	FY 2023Dec 29, 2023	FY 2024Dec 27, 2024	FY 2025Jan 2, 2026
Revenue	163,460	230,472	284,391	322,415	313,901	239,442
Revenue from contracts with customers	22,053	—	—	—	—	—
Cost of goods and services sold	45,098	51,835	61,008	69,764	74,319	57,022
Gross profit	118,362	178,637	223,383	252,651	239,582	182,420
Research and development	31,918	33,862	35,983	44,401	53,973	40,055
Selling, general and administrative	111,593	145,298	179,581	224,554	252,193	274,133
General and administrative	33,911	44,142	54,742	72,319	89,898	85,783
Operating income (loss)	6,769	33,339	43,802	28,097	(12,611)	(91,713)
Other income (expense)	(44)	(48)	205	448	815	2,253
Income tax expense (benefit)	2,354	6,803	6,797	12,349	11,156	(1,815)
Net income (loss)	5,913	24,501	38,755	21,347	(20,208)	(80,448)
Earnings per share, basic USD per share	0.13	0.52	0.81	0.44	(0.41)	(1.62)
Earnings per share, diluted USD per share	0.12	0.50	0.78	0.43	(0.41)	(1.62)
Weighted average shares, basic thousands of shares	45,605	47,210	47,987	48,523	49,125	49,568
Weighted average shares, diluted thousands of shares	47,953	49,456	49,380	49,427	49,125	49,568

Fiscal years (STAA's year ends in early January)

In thousands of dollars	FY 2020Jan 1, 2021	FY 2021Dec 31, 2021	FY 2022Dec 30, 2022	FY 2023Dec 29, 2023	FY 2024Dec 27, 2024	FY 2025Jan 2, 2026
Cash and cash equivalents	152,453	199,706	86,480	183,038	144,159	153,150
Short-term investments	—	—	125,159	37,688	86,335	34,386
Accounts receivable	35,229	43,531	62,447	94,704	77,897	50,064
Total current assets	216,418	271,411	311,723	365,269	367,940	311,545
Property and equipment, net	24,030	35,912	50,921	66,835	84,889	73,323
Right-of-use asset	8,764	31,310	30,270	34,387	36,850	29,609
Goodwill	1,786	1,786	1,786	1,786	1,786	1,786
Total assets	257,416	345,778	414,898	488,692	509,524	451,678
Accounts payable	7,874	8,699	11,576	13,557	16,704	11,574
Total current liabilities	41,236	48,802	51,716	65,036	70,306	68,504
Lease liability, non-current	6,537	28,269	27,136	31,425	34,807	32,481
Total liabilities	60,194	87,220	82,706	102,738	112,189	107,494
Accumulated deficit	(135,891)	(111,390)	(72,635)	(47,368)	(67,576)	(148,024)
Total stockholders' equity	197,222	258,558	332,192	385,954	397,335	344,184
Total liabilities and equity	257,416	345,778	414,898	488,692	509,524	451,678
Common shares outstanding (cover page) thousands of shares	46,565	47,755	48,236	48,866	49,325	49,513

Fiscal years (STAA's year ends in early January)

In thousands of dollars	FY 2020Jan 1, 2021	FY 2021Dec 31, 2021	FY 2022Dec 30, 2022	FY 2023Dec 29, 2023	FY 2024Dec 27, 2024	FY 2025Jan 2, 2026
Net income (loss)	5,913	24,501	38,755	21,347	(20,208)	(80,448)
Stock-based compensation	12,146	14,605	20,371	23,516	27,210	30,588
Net cash from operating activities	20,951	43,962	35,715	14,594	15,725	(34,230)
Purchases of property and equipment	8,404	13,645	18,108	18,188	23,394	5,820
Net cash from investing activities	(8,404)	(13,645)	(156,376)	74,347	(59,217)	46,339
Share repurchases	—	—	—	—	—	6,461
Net cash from financing activities	19,571	17,793	8,297	7,415	5,724	(4,555)
Net change in cash	32,485	47,253	(113,226)	96,558	(38,879)	8,991

SIC 3851 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3851 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Quarter
Staar Surgical	148,579	93,535	19,690*	50.1M	Q2 FY26 10-QJul 3, 2026
National Vision Holdings	35,998	498,805	8,110*	79.1M	Q2 FY26 10-QJul 4, 2026
Bausch & Lomb	513,000	1,375,000	233,000*	357.5M	Q3 FY26 10-QSep 30, 2026
RxSight	66,717	24,546	45,216*	41.9M	Q3 FY26 10-QSep 30, 2026
Warby Parker	292,674	235,511	29,618*	not reported	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.